Is zoetis a good investment?

Is Zoetis overvalued?

Zoetis’s 3-year average EBITDA growth rate is 12.3%, which ranks in the middle range of the companies in Drug Manufacturers industry. In conclusion, the stock of Zoetis (NYSE:ZTS, 30-year Financials) is estimated to be significantly overvalued. The company’s financial condition is fair and its profitability is strong.

Does Zoetis stock split?

According to our Zoetis stock split history records, Zoetis has had 0 splits. Zoetis (ZTS) has 0 splits in our Zoetis stock split history database. Looking at the Zoetis stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today.

Is ZTS stock a buy?

For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment.

Momentum Scorecard. More Info.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.60%
2 Buy 19.21%
3 Hold 10.85%
4 Sell 6.62%

When did zoetis split from Pfizer?

On May 16, 2013, Zoetis, which only three months earlier had been spun off from Pfizer as a completely independent company, got some very welcome news — an FDA approval for APOQUEL (oclacitinib tablet), which helps control severe itching associated with allergic dermatitis in dogs 12 months of age or older.

What is zoetis used for?


Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming.

THIS IS INTERESTING:  What should be included in an investment portfolio?